Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CareDx, Inc.CDNA · Entity 4344 | Director | August 05, 2026 | August 06, 2026 |
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director | March 21, 2018 | March 22, 2018 |
| Innoviva, Inc.INVA · Entity 4679 | Director | April 25, 2022 | April 27, 2022 |
| Sio Gene Therapies Inc.AXGT · Entity 130622 | Director | April 15, 2019 | April 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CareDx, Inc.
Report date August 05, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,061 |
Reported balance
After 2026-08-05 transaction · row 1
1 source rowRow 1 · 2026-08-05 · Sale · Disposed 20,000 · Balance 134,061 F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.14 to $47.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.14 to $47.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
INOVIO PHARMACEUTICALS, INC.
Report date March 21, 2018 · Filed March 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,090 |
Reported balance
After 2018-03-21 transaction · row 1
1 source rowRow 1 · 2018-03-21 · Exercise / conversion · Acquired 4,090 · Balance 4,090 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 8,180 |
Reported balance
After 2018-03-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-21 · Exercise / conversion · Disposed 4,090 · Balance 8,180 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.
Innoviva, Inc.
Report date April 25, 2022 · Filed April 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,207 |
Reported balance
After 2022-04-25 transaction · row 1
1 source rowRow 1 · 2022-04-25 · Grant · Acquired 12,647 · Balance 137,207 F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
| Non-statutory Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.79 · Expires 2032-04-24 | Direct | 10,000 |
Reported balance
After 2022-04-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-04-25 · Grant · Acquired 10,000 · Balance 10,000 F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.
Sio Gene Therapies Inc.
Report date April 15, 2019 · Filed April 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2029-04-14 | Direct | 255,000 |
Reported balance
After 2019-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-15 · Grant · Acquired 255,000 · Balance 255,000 F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARIAD PHARMACEUTICALS INC
Report date February 16, 2017 · Filed February 16, 2017
Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 1
1 source rowRow 1 · 2017-02-16 · Disposition to issuer · Disposed 18,008 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.65 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-16 · Disposition to issuer · Disposed 75,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.82 | Direct | 0 |
Reported balance
After 2017-02-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.
F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2020 Filed Dec 15, 2020 00:50 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 3,224 | $72.04 | $232,247.93 |
DisclosureSEC source: 0001217234-20-000200 · wf-form4_160799340480498.xml · nonDerivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,563 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $71.67 to $72.65, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 00:50 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 4,700 | $71.10 | $334,177.05 |
DisclosureSEC source: 0001217234-20-000200 · wf-form4_160799340480498.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,787 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $70.67 to $71.66, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 22:41 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 444 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-20-000176 · wf-form4_160167847918469.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,487 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 15:49 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 527 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-20-000117 · wf-form4_159405052901914.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,043 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| June 18, 2020 Filed Jun 20, 2020 01:12 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 4,978 | $31.35 Strike: $31.35 | $156,060.30 |
DisclosureSEC source: 0001217234-20-000098 · wf-form4_159261553628523.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,978 Underlying: Common Stock · 4,978 shares Expires 2030-06-18 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 18, 2020 and the shares subject to the option shall vest monthly thereafter through June 18, 2021. Read SEC document |
| June 18, 2020 Filed Jun 20, 2020 01:12 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 3,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-20-000098 · wf-form4_159261553628523.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,847 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 18, 2021. Read SEC document |
| May 13, 2020 Filed May 13, 2020 21:28 UTC | CareDx, Inc. CDNA · Entity 4344 | SaleCommon Stock | 10,000 | $27.65 | $276,458.00 |
DisclosureSEC source: 0001217234-20-000065 · wf-form4_158940532053454.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,657 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.06, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-008545 · doc1.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,078 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 01, 2020 Filed Jul 6, 2020 15:41 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 669 | $0.00 | $0.00 |
DisclosureSEC source: 0001217234-20-000115 · wf-form4_159405008301609.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,326 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 02:06 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 653 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-000414 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,657 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 21:20 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 541 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024744 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,004 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 01:12 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 468 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-018991 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,463 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 22:01 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 4,152 | $38.26 Strike: $38.26 | $158,855.52 |
DisclosureSEC source: 0000899243-19-017462 · doc4.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,152 Underlying: Common Stock · 4,152 shares Expires 2029-06-17 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 17, 2019 and the shares subject to the option shall vest monthly thereafter through June 17, 2020. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 22:01 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 2,613 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-017462 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,995 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 17, 2020. Read SEC document |
| April 24, 2019 Filed May 25, 2019 01:57 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-031860 · a4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,161 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 01:33 UTC | CareDx, Inc. CDNA · Entity 4344 | OtherWarrant (right to buy) · Derivative | 4,415 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0000899243-19-010853 · doc4.xml · derivative · entry 3 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,415 shares Expires 2023-06-17 Read SEC document |
| April 16, 2019 Filed Apr 18, 2019 01:33 UTC | CareDx, Inc. CDNA · Entity 4344 | OtherCommon Stock | 4,415 | $1.12 | $4,944.80 |
DisclosureSEC source: 0000899243-19-010853 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,382 Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 01:33 UTC | CareDx, Inc. CDNA · Entity 4344 | PurchaseWarrant (right to buy) · Derivative | 4,415 | $28.26 Strike: $1.12 | $124,767.90 |
DisclosureSEC source: 0000899243-19-010853 · doc4.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,415 Underlying: Common Stock · 4,415 shares Expires 2023-06-17 Read SEC document |
| April 15, 2019 Filed Apr 18, 2019 01:20 UTC | Sio Gene Therapies Inc. AXGT · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 255,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-19-025195 · doc4.xml · derivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Shares · 255,000 shares Expires 2029-04-14 F1 · derivative.exercise_date: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:27 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-009901 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,967 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| March 21, 2019 Filed Mar 21, 2019 23:12 UTC | CareDx, Inc. CDNA · Entity 4344 | OtherWarrant (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0000899243-19-008750 · doc4.xml · derivative · entry 6 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2021-06-17 Read SEC document |
| March 21, 2019 Filed Mar 21, 2019 23:12 UTC | CareDx, Inc. CDNA · Entity 4344 | OtherWarrant (right to buy) · Derivative | 7,980 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0000899243-19-008750 · doc4.xml · derivative · entry 5 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,980 shares Expires 2021-06-17 Read SEC document |
| March 21, 2019 Filed Mar 21, 2019 23:12 UTC | CareDx, Inc. CDNA · Entity 4344 | OtherCommon Stock | 25,000 | $1.12 | $28,000.00 |
DisclosureSEC source: 0000899243-19-008750 · doc4.xml · nonDerivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,453 Read SEC document |
| March 21, 2019 Filed Mar 21, 2019 23:12 UTC | CareDx, Inc. CDNA · Entity 4344 | OtherCommon Stock | 7,980 | $1.12 | $8,937.60 |
DisclosureSEC source: 0000899243-19-008750 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,453 Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 23:12 UTC | CareDx, Inc. CDNA · Entity 4344 | PurchaseWarrant (right to buy) · Derivative | 25,000 | $36.14 Strike: $1.12 | $903,500.00 |
DisclosureSEC source: 0000899243-19-008750 · doc4.xml · derivative · entry 4 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2021-06-17 Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 23:12 UTC | CareDx, Inc. CDNA · Entity 4344 | PurchaseWarrant (right to buy) · Derivative | 7,980 | $36.14 Strike: $1.12 | $288,397.20 |
DisclosureSEC source: 0000899243-19-008750 · doc4.xml · derivative · entry 3 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,980 Underlying: Common Stock · 7,980 shares Expires 2021-06-17 Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:19 UTC | Innoviva, Inc. INVA · Entity 4679 | PurchaseCommon Stock | 15,000 | $15.90 | $238,500.00 |
DisclosureSEC source: 0001567619-19-005602 · doc1.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,762 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:27 UTC | Innoviva, Inc. INVA · Entity 4679 | PurchaseCommon Stock | 10,000 | $14.90 | $148,958.00 |
DisclosureSEC source: 0001567619-19-005282 · doc1.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,762 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 02:11 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 535 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000351 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,473 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 01:11 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-025909 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,938 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 21:26 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | PurchaseCommon Shares | 25,000 | $2.07 | $51,750.00 |
DisclosureSEC source: 0001209191-18-046472 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $2.0449 to $2.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 21:29 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 1,197 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019272 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,204 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| June 20, 2018 Filed Jul 3, 2018 21:15 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000899243-18-019255 · doc4.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-20 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 20, 2018 and the shares subject to the option shall vest monthly thereafter through June 20, 2019. Read SEC document |
| June 20, 2018 Filed Jul 3, 2018 21:15 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019255 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,007 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 20, 2019. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 20:10 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 14,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005883 · edgar.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,762 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:52 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 2,221 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009490 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,007 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 18:17 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 4,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000016 · wf-form4_152174260902007.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,180 Underlying: Common Stock · 4,090 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 18:17 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 4,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-18-000016 · wf-form4_152174260902007.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:43 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | PurchaseCommon Shares | 25,000 | $1.50 | $37,425.00 |
DisclosureSEC source: 0001209191-18-015057 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 22:44 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001209191-18-010479 · doc4.xml · derivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2028-02-12 F1 · derivative.exercise_date: The common shares underlying this option vest over a period of three years, with one-third of the common shares vesting on each of the first, second and third anniversaries of February 11, 2018, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 01:51 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 2,004 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000155 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,786 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 23:12 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 14,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015801 · edgar.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,513 Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:05 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantOption to Purchase Common Stock · Derivative | 6,679 | Not disclosed Strike: $5.49 | Not disclosed |
DisclosureSEC source: 0000899243-17-026009 · doc4.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,679 Underlying: Common Stock · 6,679 shares Expires 2024-11-09 F3 · security: Represents a stock option granted pursuant to the Exchange Offer (the "New Options"). F4 · derivative.exercise_price: The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017. F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares. F5 · derivative.exercise_date: The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, F6 · derivative.exercise_date: (Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:05 UTC | CareDx, Inc. CDNA · Entity 4344 | Disposition to issuerOption to Purchase Common Stock · Derivative | 10,948 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-026009 · doc4.xml · derivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,948 shares Expires 2024-06-19 F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares. F1 · derivative.exercise_date: The shares underlying the cancelled option were vested and immediately exercisable. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 21:57 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 5,951 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-023568 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,782 F1 · shares: Represents an automatic quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 21:16 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 15,000 | $1.22 Strike: $1.22 | $18,300.00 |
DisclosureSEC source: 0000899243-17-018287 · doc4.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-07-13 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on August 13, 2017 and the shares subject to the option shall vest monthly thereafter through July 13, 2018. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 21:16 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018287 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,831 F1 · shares: The reported securities are represented by restricted stock units which shall vest on July 13, 2018. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 22:16 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 9,910 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017859 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,831 F1 · shares: Represents an automatic, quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document |
| May 12, 2017 Filed May 15, 2017 21:28 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 12,500 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001055726-17-000031 · wf-form4_149488369205488.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-12 F2 · derivative.exercise_date: Options to vest 100% on May 12, 2018. Read SEC document |
| May 12, 2017 Filed May 15, 2017 21:28 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 7,669 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001055726-17-000031 · wf-form4_149488369205488.xml · derivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,669 Underlying: Common Stock · 7,669 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 12, 2018. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 12, 2018. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 12, 2018. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 12, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.